UBE2D1 Antibodies

Ubiquitin-conjugating enzyme E2 D1 (UBE2D1)

Accepts ubiquitin in the E1 complex and catalyzes its covalent attachment to other proteins (PubMed:22496338). Mediates the selective degradation of short-lived and abnormal proteins.

Functions in the E6/E6-AP-induced ubiquitination of p53/TP53. Mediates ubiquitination of PEX5 and auto-ubiquitination of STUB1, TRAF6 and TRIM63/MURF1 (PubMed:18042044, PubMed:18359941).

Gene Information

Human
Gene Name:	UBE2D1
Uniprot:	P51668
Entrez:	7321

Family

Belongs to:
ubiquitin-conjugating enzyme family

Alternative Names

E2(17)KB1; Stimulator of Fe transportUBC4/5 homolog; UBC4/5; UBC5A; UbcH5; UbcH5a; UBCH5AEC 6.3.2.19; UBCH5SFT; UBE2D1; Ubiquitin carrier protein D1; ubiquitin-conjugating enzyme E2 D1; Ubiquitin-conjugating enzyme E2(17)KB 1; Ubiquitin-conjugating enzyme E2-17 kDa 1; ubiquitin-conjugating enzyme E2D 1 (UBC4/5 homolog, yeast); Ubiquitin-protein ligase D1

Molecular Weight

Mass (kDA):
16.602 kDA

Genomic Context

Human
Location:	10q21.1
Sequence:	10; NC_000010.11 (58334979..58370753)

Tissue Specificity

Ubiquitous. Up-regulated in livers of iron- overloaded patients with hereditary hemochromatosis.

Subcellular Localizations

Cytoplasm.

Diseases

• Solitary Fibrous Tumor
• Hemochromatosis
• Neoplasms
• Iron Overload
• Hereditary Hemochromatosis
• Anemia
• Iron Deficiency
• Nephropathy Toxic
• Carcinoma
• Fibrosis
• Malignant Neoplasms
• Acute Promyelocytic Leukemia

• Disease Caused By Shigella Flexneri
• Iron Deficiency Anemia
• Shigella Infections
• Von Hippel-lindau Syndrome
• Innate Immune Response
• Deficiency Anaemia
• Virus Diseases

Interacting Proteins

• DTX2
• DTX3
• MID1
• MKRN2
• MKRN3

• OTUB1
• RING1
• RNF11
• RNF111
• RNF115

• RNF126
• RNF14
• Rnf146
• RNF181
• RNF185

• RNF2
• RNF25
• Rnf4
• RNF5
• TRAF6

• TRIM39
• TRIM8
• XIAP
• ZNRF1

Pathways

• Transport
• Conjugation
• Localization
• Rna Interference
• Secretion
• Protein Phosphorylation
• Photomorphogenesis
• Immune Response
• Inflammatory Response
• Translation
• Cell Cycle

• Innate Immune Response
• Iron Assimilation
• S Phase
• Cell Growth
• Oncogenesis

PTMs

• Ubiquitination
• Phosphorylation

• Hydroxylation
• Cleavage

Research Areas

• Cancer
• Hypoxia

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/UBE2D1

Best Uses Of The UBE2D1 Marker

If you're looking for the best antibodies for the UBE2D1 marker, you've come to the right place. Boster offers high-affinity primary antibodies that have been validated in Western Blotting, Immunohistochemistry, and ELISA. The high-affinity antibodies from Boster are cited over 25 years and are trusted by the research community.

Steven Boster

Currently, the UBE2D1 marker has found many applications in cancer research. For example, it has been shown to reduce SMAD4 ubiquitination and degradation in cancer cells. This method has been used to study the function of the UBE2D1 gene in various contexts, including wound healing. In one study, UBE2D1 expression was associated with metastasis.

Using the UBE2D1 marker, scientists have been able to inhibit the migration of MGC-803 cells in vitro. This resulted in a higher proportion of migrating cells in one study compared to a control group. Additionally, cells treated with UBE2D1 overexpression displayed higher levels of MMP2 and MMP9 protein. This study also revealed the potential for the UBE2D1 marker to prevent the migration of cancer cells in vivo.

In addition to gastric cancer, the UBE2D1 marker has also been found in a number of other cancers. It may be a candidate gene for gene therapy in the treatment of this disease. For example, a recent study showed that UBE2D1 expression was elevated in 25 pairs of GC tissue and paracancerous tissues. Moreover, the UBE2D1 gene was associated with poor survival outcomes, which may be related to its role in p53 degradation.

High-affinity primary antibodies

Developing high-affinity primary antibodies using the UBE2-D1 marker is a challenging process, but with these new compounds, it becomes easier than ever to develop highly specific antibodies. In fact, UBE2D1 is a well-known target of the UBE2QL1 antibody. UBE2QL1 is a critical component of the lysosomal membrane. Without it, the cells fail to properly degrade the lysosome and are destroyed.

The E2-E3 axis has been identified as a potential target of anticancer agents. There are at least 50 E2 proteins in the human proteome. They play a key role in pancreatic cancer. The pancreatic tumors with high levels of Ubch20 have increased expression of Ubch20, which correlates with clinical stage and lymph node metastasis. UBE2C is also associated with the survival of pancreatic cancer cells. Antibodies that inhibit UbcH5c expression inhibit cell proliferation and cell migration.

The UBE2QL1-APEX2 conjugate has been developed by cloning the human UBE2QL1 gene into pDNR221 or pcDNA5FRT/TO-HA (N-terminal). The resulting protein is an eluent of amino acids with high affinity. It is highly purified and stable, allowing for easy detection of antigens.

The knockout effect of UBE2D1 is not yet known, but it is still the dominant ubiquitin E2 enzyme. The enzyme governs the ubiquitination and destruction of cereblon neomorphic substrates, but Ube2D3 partially rescues the degradation phenotype in Ube2G1 knockout cells. The depletion efficiency of Ube2D3 has been demonstrated in experiments by an independent group.

The UBE2QL1 protein was also depleted by siRNA targeting the open reading frame of the gene. The knockdown efficiency was similar to that observed in the screen, but siRNAs #4 and #5 reduced the signal on lysosomes. Thus, the UBE2QL1 protein may be essential in HeLa cells. The results of this study are a good example of UBE2D1-directed research.

The high-affinity ubiquitin-conjugating E2s, which include UBE2G1 and UBE2D1, function with the CRL4-DDB1-CRBN ubiquitin ligase complex. The study identified these two E2s using a CRISPR-CAS screen, where the polyubiquitin-conjugating enzyme IKZF1 was monitored for degradation.

Clinical applications

The functional role of the UBE2D1 gene in human HCC is unclear. However, a recent study found that its genomic level correlates with the gender of HCC patients. The UBE2D1 gene is located at a common fragile site (FRA10C) which is prone to rearrangements in the presence of replication stress. This finding suggests that the UBE2D1 gene may have important roles in a variety of human cancers.

A study in GSE14520 patients revealed that the expression of UBE2D1 was associated with a shorter overall survival compared with controls. UBE2D1 is overexpressed in both cancerous and premalignant tissues, and it was found to be an independent prognostic marker for HCC patients. Further studies are needed to confirm this association in human HCC patients. The current treatment for HCC is sorafenib, which is not effective in some patients.

A recent study in the United States found that a high UBE2D1 expression level was associated with a poor prognosis in patients with HCC. In addition, UBE2D1 was shown to promote the growth of HCC cells both in vitro and in vivo. Furthermore, high levels of UBE2D1 were associated with a high serum level of IL-6, a cytokine that stimulates the DNA damage response and suppresses the nuclear factor p53. Therefore, the UBE2D1 gene may represent a new axis of cytokines in the initiation and progression of HCC.

The UBE2D1 gene is a member of the UBE2D gene family. It plays an important role in p53-mediated ubiquitination of p53. Until recently, however, its exact biological function was not known. The discovery of this gene has opened new avenues for cancer treatment and research. This marker may also be used to monitor tumor progression and monitor tumor growth.

In the study of GSE29272 patients, miR-144-3p inversely correlated with UBE2D1 levels. Interestingly, the miR-144-3p protein suppresses UBE2D1 expression in cells derived from GC patients. These findings are important because it may help determine the sensitivity and efficacy of treatments. Its implication in GC treatment depends on the level of UBE2D1 protein expression in patients with this gene mutation.

In a study of GC patients, researchers found that the level of HCG11 and UBE2D1 was elevated in tumor tissues. They also noted that the expression of miR-144-3p in GC cells is reduced by HCG11 knockdown. These data suggest that the UBE2D1-miR-144-3p axis is a novel therapeutic target that could impede DDP resistance in GC.